JP2005529934A - キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス - Google Patents

キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス Download PDF

Info

Publication number
JP2005529934A
JP2005529934A JP2004509683A JP2004509683A JP2005529934A JP 2005529934 A JP2005529934 A JP 2005529934A JP 2004509683 A JP2004509683 A JP 2004509683A JP 2004509683 A JP2004509683 A JP 2004509683A JP 2005529934 A JP2005529934 A JP 2005529934A
Authority
JP
Japan
Prior art keywords
compound
group
alkyl
cycloalkyl
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004509683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529934A5 (US07786301-20100831-C00009.png
Inventor
ビラス エイチ． ダハヌカー，
ホア エヌ． グェン，
セシリア エー． オール，
フチェン ザン，
イリア エー． ザビアラブ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005529934A publication Critical patent/JP2005529934A/ja
Publication of JP2005529934A5 publication Critical patent/JP2005529934A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
JP2004509683A 2002-05-31 2003-05-30 キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス Pending JP2005529934A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38447802P 2002-05-31 2002-05-31
PCT/US2003/017042 WO2003101992A1 (en) 2002-05-31 2003-05-30 Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Publications (2)

Publication Number Publication Date
JP2005529934A true JP2005529934A (ja) 2005-10-06
JP2005529934A5 JP2005529934A5 (US07786301-20100831-C00009.png) 2006-07-06

Family

ID=29712039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004509683A Pending JP2005529934A (ja) 2002-05-31 2003-05-30 キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス

Country Status (17)

Country Link
US (2) US7074923B2 (US07786301-20100831-C00009.png)
EP (1) EP1509525B9 (US07786301-20100831-C00009.png)
JP (1) JP2005529934A (US07786301-20100831-C00009.png)
CN (2) CN100497336C (US07786301-20100831-C00009.png)
AR (1) AR040232A1 (US07786301-20100831-C00009.png)
AT (1) ATE336494T1 (US07786301-20100831-C00009.png)
AU (1) AU2003238822A1 (US07786301-20100831-C00009.png)
CA (1) CA2483923A1 (US07786301-20100831-C00009.png)
CY (1) CY1105774T1 (US07786301-20100831-C00009.png)
DE (1) DE60307628T2 (US07786301-20100831-C00009.png)
DK (1) DK1509525T5 (US07786301-20100831-C00009.png)
ES (1) ES2270047T3 (US07786301-20100831-C00009.png)
HK (1) HK1068139A1 (US07786301-20100831-C00009.png)
MX (1) MXPA04011862A (US07786301-20100831-C00009.png)
PT (1) PT1509525E (US07786301-20100831-C00009.png)
WO (1) WO2003101992A1 (US07786301-20100831-C00009.png)
ZA (1) ZA200408719B (US07786301-20100831-C00009.png)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
CA2533715A1 (en) 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
AR047948A1 (es) * 2003-11-21 2006-03-15 Schering Corp Formulaciuones de inhibidores de la fosfodiesterasa v
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
JPH0374369A (ja) * 1989-06-01 1991-03-28 Merck & Co Inc アンギトテンシン２拮抗剤
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH09510983A (ja) * 1994-04-05 1997-11-04 ヘキスト・アクチエンゲゼルシヤフト 好酸球の顆粒球の病理学的な過剰反応性を減少するためのキサンチン誘導体の使用、新規なキサンチン化合物およびそれらの製法
JPH1059969A (ja) * 1996-06-07 1998-03-03 Hoechst Ag ショック状態の治療および予防用のテオフィリン誘導体の使用、新規キサンチン化合物およびその製造方法
WO2002024698A1 (en) * 2000-09-19 2002-03-28 Schering Corporation Xanthine phosphodiesterase v inhibitors
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
CA2030112A1 (en) * 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
JPH04279586A (ja) * 1991-03-05 1992-10-05 Hokuriku Seiyaku Co Ltd キサンチン誘導体
DE59208572D1 (de) * 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
HUP0301622A3 (en) * 2000-07-04 2006-05-29 Novo Nordisk As Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
EP1463727A2 (en) * 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
EP1442042A1 (en) 2001-11-09 2004-08-04 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
ATE409466T1 (de) * 2002-01-11 2008-10-15 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
KR101150449B1 (ko) * 2002-08-21 2012-06-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AU2003280680A1 (en) * 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CA2533715A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0374369A (ja) * 1989-06-01 1991-03-28 Merck & Co Inc アンギトテンシン２拮抗剤
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH09510983A (ja) * 1994-04-05 1997-11-04 ヘキスト・アクチエンゲゼルシヤフト 好酸球の顆粒球の病理学的な過剰反応性を減少するためのキサンチン誘導体の使用、新規なキサンチン化合物およびそれらの製法
JPH1059969A (ja) * 1996-06-07 1998-03-03 Hoechst Ag ショック状態の治療および予防用のテオフィリン誘導体の使用、新規キサンチン化合物およびその製造方法
WO2002024698A1 (en) * 2000-09-19 2002-03-28 Schering Corporation Xanthine phosphodiesterase v inhibitors
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6009061609, ＢＲＩＤＳＯＮ，Ｐ．Ｋ． ｅｔ ａｌ, "Ｓｙｎｔｈｅｓｉｓ ａｎｄ ａｄｅｎｏｓｉｎｅ ｒｅｃｅｐｔｏｒ ａｆｆｉｎｉｔｙ ｏｆ ７−β−Ｄ−ｒｉｂｏｆｕｒａｎｏｓｙｌｘａｎｔｈｉｎｅ", Ｎｕｃｌｅｏｓｉｄｅｓ ＆ Ｎｕｃｌｅｏｔｉｄｅｓ, 1998, Ｖｏｌ．１７， Ｎｏ．４, ｐｐ．７５９−７６８ *
JPN6009061611, ＰＯＮＣＥ，Ｍ．Ａ． ｅｔ ａｌ, "Ｓｙｎｔｈｅｓｉｓ ａｎｄ ｉｓｏｌａｔｉｏｎ ｏｆ ｂｒｏｍｏ−β−ｃａｒｂｏｌｉｎｅｓ ｏｂｔａｉｎｅｄ ｂｙ ｂｒｏｍｉｎａｔｉｏｎ ｏｆ β−ｃａｒｂｏｌｉｎｅ ａｌｋａｌｏｉｄｓ", Ｊｏｕｒｎａｌ ｏｆ Ｈｅｔｅｒｏｃｙｃｌｉｃ Ｃｈｅｍｉｓｔｒｙ, 2001, Ｖｏｌ．３８， Ｎｏ．５, ｐｐ．１０８７−１０９５ *
JPN6009061613, 実験化学講座２０ 第４版, 1992, ｐｐ．１７５−１７９ *
JPN6009061614, ＢＲＩＤＳＯＮ，Ｐ．Ｋ． ｅｔ ａｌ, "１−Ｓｕｂｓｔｉｔｕｔｅｄ ｘａｎｔｈｉｎｅｓ", Ｓｙｎｔｈｅｓｉｓ, 1995, Ｎｏ．７, ｐｐ．８５５−８５８ *

Also Published As

Publication number Publication date
US7074923B2 (en) 2006-07-11
CN100497336C (zh) 2009-06-10
CN1668618A (zh) 2005-09-14
DE60307628D1 (de) 2006-09-28
US20030232987A1 (en) 2003-12-18
CN101538224A (zh) 2009-09-23
WO2003101992A1 (en) 2003-12-11
EP1509525B1 (en) 2006-08-16
DK1509525T5 (da) 2007-07-30
AR040232A1 (es) 2005-03-23
EP1509525B9 (en) 2007-10-31
PT1509525E (pt) 2006-12-29
HK1068139A1 (en) 2005-04-22
MXPA04011862A (es) 2005-03-31
ZA200408719B (en) 2005-11-15
CY1105774T1 (el) 2011-02-02
CA2483923A1 (en) 2003-12-11
EP1509525A1 (en) 2005-03-02
ES2270047T3 (es) 2007-04-01
DK1509525T3 (da) 2006-12-11
DE60307628T2 (de) 2007-08-09
US20060205943A1 (en) 2006-09-14
ATE336494T1 (de) 2006-09-15
US7786301B2 (en) 2010-08-31
AU2003238822A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
JP2005529934A (ja) キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス
JP6061158B2 (ja) ６−（７−（（１−アミノシクロプロピル）メトキシ）−６−メトキシキノリン−４−イルオキシ）−ｎ−メチル−１−ナフトアミド、またはそれの薬学的に許容される塩の合成中間体およびその使用
EP2190804B1 (en) Process and intermediates for preparing integrase inhibitors
EP2069280B1 (en) Process and intermediates for preparing HIV integrase inhibitors
JP3378315B2 (ja) カルバゾロン誘導体及びその調製方法
AU2008313425B2 (en) Improved process for preparing 2-(substituted phenyl)-2-hydroxy-ethyl carbamates
EP1719772A1 (en) Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
EP2217585A2 (en) Process for the preparation of 2h-chromene-3-carbamate derivatives
HU200459B (en) New process for producing 7-bromo-beta-carboline compounds
US7223871B2 (en) Process for preparing substituted imidazole derivatives and intermediates used in the process
WO2020020190A1 (zh) 一种喹啉衍生物的合成方法
EP0254611B1 (fr) Dérivés 8-phénylthiotétrahydroquinoléines substitués et leurs sels, leur préparation à titre de médicaments et les compositions les renfermant
EP0269841B1 (fr) 1-Hydroxyalkylxanthines, leurs procédés de préparation et médicament les contenant
JPH06279414A (ja) アリールヒダントインの製造方法
EP0713865A1 (fr) Dérivés d'acide 2-aminobenzènesulfonique et de chlorure de 2-aminobenzènesulfonyle, leur préparation et leur utilisation comme intermédiaires de synthèse
JPH0339072B2 (US07786301-20100831-C00009.png)
JPH0623180B2 (ja) シアノグアニジン誘導体及びその製造法
BE897358A (fr) Derives amines de benzylidene-pyrrolo [2,1-b] quinazolines et de benzylidene-pyrido [2,1-b] quinazolines
FR2614619A1 (fr) Procede de preparation de n-((chloro-2)-benzyl) (thienyl-2)-2 ethylamine
HU204771B (en) Process for producing anilinofumarates from chloromaleates or chlorofumarates or from their mixture
GB2104508A (en) Improved process for the preparation of 2,4,-diamino-5-(3',4',5'-trimethoxy-benzyl) pyrimidine
HU193186B (en) Process for producing benzothiazine derivative
WO2009002955A1 (en) Process for the preparation of (2r)-2-[4-(7-bromo-2-quinolyloxy)phenoxy]propanoic acid
JP2002512174A (ja) 芳香族チオール及び誘導体の調製方法、並びに試薬、中間生成物及びそれらの生成方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100524